Clinical Trial

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Name: A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer — clinical trial record (NCT07644286)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study aims to evaluate the safety, tolerability, and efficacy of pirfenidone and PD-1 monoclonal antibody combined with or without hypofractionated radiotherapy in the treatment of advanced refractory pMMR/MSS colorectal cancer patients.

Trial Details

NCT Number	NCT07644286
Lead Sponsor	Tao Zhang
Conditions	Colorectal Cancer (CRC)
Enrollment	48 participants
Start Date	2025-12-01
Primary Completion	2027-01-25 (estimated)
Study Completion	2027-12-25 (estimated)
Updated on ClinicalTrials.gov	2026-06-12